← Back to Search

Lonigutamab for Thyroid Eye Disease (TED Trial)

Phase 1 & 2
Recruiting
Research Sponsored by ValenzaBio, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 to day 169

Summary

This trial is testing a new medication called lonigutamab to help people with Thyroid Eye Disease (TED). TED causes eye problems due to thyroid issues. Lonigutamab may work by reducing inflammation and other symptoms in the eyes.

Who is the study for?
This trial is for men and women aged 18-70 with Thyroid Eye Disease (TED), showing eye protrusion and active symptoms within the last 15 months. Participants must have a Clinical Activity Score of at least 4, indicating active disease. They should not have had certain treatments for TED or conditions like inflammatory bowel disease, hearing loss, optic neuropathy, diabetes with high hemoglobin A1c levels, or recent steroid use.
What is being tested?
The study tests Lonigutamab's effectiveness and safety in treating TED compared to a placebo. It's a Phase 1/2 trial where multiple doses are given to participants across various centers. The goal is to see if Lonigutamab can help reduce the severity of TED symptoms.
What are the potential side effects?
While specific side effects for Lonigutamab aren't listed here, common side effects from similar treatments may include reactions at the injection site, headaches, muscle pains, possible immune system responses affecting different organs.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 to day 169
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 to day 169 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence and characterization of nonserious treatment emergent adverse events (TEAEs)
Incidence and characterization of serious treatment emergent adverse events (TEAEs)
Secondary study objectives
PK profile of lonigutamab

Trial Design

4Treatment groups
Experimental Treatment
Group I: Cohort 4Experimental Treatment1 Intervention
multiple doses of lonigutamab dose 4 administered SC injection every 4 or 3 weeks.
Group II: Cohort 3Experimental Treatment2 Interventions
multiple doses of lonigutamab dose 3 administered SC injection every 4 weeks.
Group III: Cohort 2Experimental Treatment2 Interventions
multiple doses of dose 2 of lonigutamab administered SC injection weekly
Group IV: Cohort 1Experimental Treatment2 Interventions
Single SC injection of dose 1 of lonigutamab or placebo at Day 1 and Day 21
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Graves' Ophthalmopathy, also known as Thyroid Eye Disease (TED), is commonly treated with corticosteroids, immunosuppressive agents, and monoclonal antibodies. Corticosteroids reduce inflammation and immune response, alleviating symptoms like swelling and redness. Immunosuppressive agents, such as methotrexate, inhibit the immune system to prevent further tissue damage. Monoclonal antibodies, like teprotumumab, target specific proteins involved in the disease process, such as the insulin-like growth factor-1 receptor (IGF-1R), to reduce inflammation and tissue expansion. These treatments are crucial for managing symptoms, preventing disease progression, and improving the quality of life for patients with Graves' Ophthalmopathy.

Find a Location

Who is running the clinical trial?

ValenzaBio, Inc.Lead Sponsor
2 Previous Clinical Trials
7 Total Patients Enrolled
ACELYRIN Inc.Lead Sponsor
8 Previous Clinical Trials
1,045 Total Patients Enrolled
Keenan, MDStudy DirectorValenzaBio, Inc.

Media Library

Placebo Clinical Trial Eligibility Overview. Trial Name: NCT05683496 — Phase 1 & 2
Graves' Ophthalmopathy Research Study Groups: Cohort 4, Cohort 3, Cohort 2, Cohort 1
Graves' Ophthalmopathy Clinical Trial 2023: Placebo Highlights & Side Effects. Trial Name: NCT05683496 — Phase 1 & 2
Placebo 2023 Treatment Timeline for Medical Study. Trial Name: NCT05683496 — Phase 1 & 2
~12 spots leftby May 2025